BioCryst to Present at 39th Annual J.P. Morgan Healthcare Conference

Rhea-AI Summary

BioCryst Pharmaceuticals (Nasdaq: BCRX) will present at the 39th Annual J.P. Morgan Healthcare Conference on January 13, 2021, at 11:40 a.m. ET via a virtual event. Interested parties can access a live audio webcast and replay through the Investors section of BioCryst’s website. The company focuses on developing oral medicines for rare diseases, with products like ORLADEYO™ approved in the U.S. for HAE prevention and others in development, including BCX9930 and galidesivir for various conditions.

RESEARCH TRIANGLE PARK, N.C., Jan. 06, 2021 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the company will present at the 39^th Annual J.P. Morgan Healthcare Conference, which is being conducted as a virtual event, on Wednesday, January 13, 2021 at 11:40 a.m. ET.

Links to a live audio webcast and replay of the presentation may be accessed in the Investors section of BioCryst’s website at http://www.biocryst.com.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals discovers novel, oral, small-molecule medicines that treat rare diseases in which significant unmet medical needs exist and an enzyme plays a key role in the biological pathway of the disease. Oral, once-daily ORLADEYO™ (berotralstat) is approved in the United States for the prevention of HAE attacks in adults and pediatric patients 12 years and older, and under regulatory review for approval in Japan and the European Union. BioCryst has several ongoing development programs including BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases, BCX9250, an ALK-2 inhibitor for the treatment of fibrodysplasia ossificans progressiva, and galidesivir, a potential treatment for Marburg virus disease and Yellow Fever. RAPIVAB^® (peramivir injection), a viral neuraminidase inhibitor for the treatment of influenza, has received regulatory approval in the U.S., Canada, Australia, Japan, Taiwan and Korea. Post-marketing commitments for RAPIVAB are ongoing. For more information, please visit the Company’s website at www.biocryst.com.

BCRXW

Investor Contact:
John Bluth
+1 919 859 7910
jbluth@biocryst.com

Media Contact:
Catherine Collier Kyroulis
+1 917 886 5586
ckyroulis@biocryst.com

FAQ

When is BioCryst Pharmaceuticals presenting at the J.P. Morgan Healthcare Conference?

BioCryst Pharmaceuticals will present on January 13, 2021, at 11:40 a.m. ET.

How can I access the BioCryst Pharmaceuticals presentation?

You can access the live audio webcast and replay on BioCryst's website under the Investors section.

What is the focus of BioCryst Pharmaceuticals?

BioCryst Pharmaceuticals focuses on discovering oral medicines for rare diseases with significant unmet medical needs.

What is ORLADEYO™ and its approval status?

ORLADEYO™ (berotralstat) is approved in the U.S. for preventing HAE attacks in patients aged 12 and above.

What other drugs are in development by BioCryst Pharmaceuticals?

BioCryst has several ongoing programs, including BCX9930, BCX9250, and galidesivir for various diseases.